Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Two immunoresistant (IR) glioma cell variants, 13-06-IR29 and 13-06-IR30, were cloned from 13-06-MG glioma cell populations after receiving continuous immunoselective pressure from multiple alloreactive cytotoxic T lymphocyte (aCTL) preparations. Reapplication of aCTL immunoselective pressure to the IR clones, displaying a partial regain in sensitivity to aCTL after removal of the selective pressure, restored the resistance. The IR variants exhibited cross-resistance to non-human leukocyte antigen (HLA)-restricted effector cells and gamma-irradiation, but not to carmustine. The IR clones were characterized for factors that might contribute to the immunoresistance. The aCTL adhesion to extracellular matrix extracts derived from either the IR clones or the parental cells was similar and not impaired. Furthermore, aCTL binding to parental cells and IR clones was equal. Down-regulation of the cell recognition molecules, class I HLA or intercellular adhesion molecule-1 (ICAM-1), that would inhibit their recognition by aCTL was not observed on the IR clones. The down-regulation of Fas by the IR clones correlated with their resistance to FasL-induced apoptosis. HLA-G or FasL that might provide an immunotolerant environment or provide a means of counterattack to aCTL, respectively, were not associated with the IR phenotype. The aCTL, coincubated with the IR clones and parental cells, displayed up-regulation of multiple secreted cytokines. A significant up-regulation of bioactive transforming growth factor (TGF)-beta was observed in the IR clones compared with the parental cells. These data suggest that increased secretion of bioactive TGF-beta may inhibit aCTL lysis of the IR clones. Disruption of the TGF-beta signaling pathway may circumvent the resistance.
Gomez
German G
GG
Department of Pathology, University of Colorado Health Sciences Center, Denver, CO, USA.
Kruse
Carol A
CA
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D017209:Apoptosis; D001932:Brain Neoplasms / Q000276:immunology*; D002118:Calcium / Q000378:metabolism; D002330:Carmustine / Q000494:pharmacology; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D018920:Coculture Techniques; D016207:Cytokines / Q000378:metabolism; D005109:Extracellular Matrix / Q000276:immunology; D053222:Fas Ligand Protein / Q000032:analysis / Q000378:metabolism; D005720:Gamma Rays; D005910:Glioma / Q000276:immunology*; D015234:HLA-A Antigens / Q000032:analysis / Q000378:metabolism; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis / Q000378:metabolism; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D015854:Up-Regulation; D019014:fas Receptor / Q000032:analysis / Q000378:metabolism
D018906:Antineoplastic Agents, Alkylating; D016207:Cytokines; D053222:Fas Ligand Protein; D015234:HLA-A Antigens; D016212:Transforming Growth Factor beta; D019014:fas Receptor; D018799:Intercellular Adhesion Molecule-1; D002118:Calcium; D002330:Carmustine